BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bristol-Myers Squibb Company (BMY) Foundation Announces Collaboration with World Health Organization's Stop TB Department to Strengthen Community Based Care of Tuberculosis Including HIV Co-Infection in Five African Countries


10/11/2011 7:36:52 AM

PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol-Myers Squibb Foundation today announced a collaboration with the World Health Organization’s (WHO) Stop TB Department for a two-year pilot initiative to strengthen community based prevention, care and control of tuberculosis (TB) including co-infection with HIV in South Africa, Tanzania, Kenya, Ethiopia and Democratic Republic of the Congo. These five countries collectively represented more than 13 percent of global TB and more than one-third of the TB/HIV co-infection burden in 2009.

The initiative is expected to be a catalyst in boosting the meaningful engagement of non-governmental and community organizations, a key objective in the WHO’s Stop TB strategy, and will draw on technical assistance through community care experts from the Bristol-Myers Squibb Foundation’s SECURE THE FUTURE® program.

“Bristol-Myers Squibb’s commitment to help communities prevail over serious diseases is embodied in our Foundation’s mission to address health disparities and empower communities,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “The hallmark of the Bristol-Myers Squibb Foundation’s SECURE THE FUTURE® program is strengthening capacity in local communities. Our work in TB and HIV co-infection has demonstrated the positive impact that community support can have on tracking, follow-up of results and treatment for infected individuals.”

The WHO will use its facilitation and brokering role with National TB and AIDS Control Programs to scale up community TB care in the five countries through strengthened engagement of non-governmental (NGOs) and community based organizations. WHO will promote the development of policies and programs that will enable greater involvement of NGOs and civil society organizations in TB community care and the creation of a more cost-effective and sustainable TB response.

This initiative offers a unique opportunity in partnership with SECURE THE FUTURE® to enhance the earlier detection of people with TB to ensure they are treated successfully, and have better access to TB services, especially in HIV prevalent settings. TB services will be strengthened and improved by embracing the advantages that NGOs can bring, such as access to remote areas and a better understanding of local needs, especially among vulnerable groups.

About the Bristol-Myers Squibb Foundation

The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease.

SECURE THE FUTURE® is the flag ship initiative of the Bristol-Myers Squibb Foundation. Since 1999, Bristol-Myers Squibb and the Bristol-Myers Squibb Foundation have committed $160 million to develop sustainable solutions for vulnerable populations, including women and children infected and affected by HIV/AIDS in Africa. Since its inception, the initiative has provided support for more than 240 projects focused on community education, outreach, medical care and research in 19 countries.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50023434&lang=en

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50023434&lang=en

Contact:

Bristol-Myers SquibbKen Dominski, 609-252-5251ken.dominski@bms.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES